News

Acorda Therapeutics to Present Update on Phase 3 Study of Inbrija In Parkinson’s Patients

Acorda Therapeutics will soon release novel data on its Phase 3 SPAN-PD trial (Study 004, NCT02240030) investigating the experimental drug Inbrija (CVT-301) as a potential therapy for patients with Parkinson’s disease. Acorda presents its poster, “Inhaled levodopa (CVT-301, 84-mg dose) significantly improves motor function during OFF periods in Parkinson’s disease…

Normast Add-on Therapy Reduces Motor, Non-motor Symptoms in Parkinson’s Patients, Study Finds

Italian researchers found that when used along with standard medication, Normast (ultra-micronized palmitoylethanolamide, or um-PEA) helped lower both motor and non-motor symptoms in patients with advanced Parkinson’s disease (PD), and slowed disease progression and disability. The study, “Ultra-micronized palmitoylethanolamide: an efficacious adjuvant therapy for Parkinson’s disease,” appeared in the journal CNS…